Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation
The tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) gene encodes the TNF-R1, one of the main TNF receptors that mediates its inflammatory actions. In a recent study, serum levels of the soluble TNF-R1 and mRNA levels of the full-length receptor were found to be significantly increas...
Saved in:
Published in | Journal of neuroimmunology Vol. 289; pp. 12 - 20 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
15.12.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 0165-5728 1872-8421 |
DOI | 10.1016/j.jneuroim.2015.10.003 |
Cover
Abstract | The tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) gene encodes the TNF-R1, one of the main TNF receptors that mediates its inflammatory actions. In a recent study, serum levels of the soluble TNF-R1 and mRNA levels of the full-length receptor were found to be significantly increased in multiple sclerosis (MS) patients carrying the R92Q mutation. Interestingly, R92Q-mutated patients were younger at disease onset and progressed slower as compared to non-carriers. Building on these previous findings, here we aimed to investigate by means of both in silico and in vitro approaches the mechanisms relating the R92Q substitution with functional changes of the receptor and their potential effects modulating MS disease course. Models of the extracellular domains of the human TNF-R1 and human TNF-R1 carrying the R92Q mutation, alone or bound to TNF, were constructed and submitted to molecular dynamics. TRAF2 and CASP3 mRNA expression levels were determined by real-time PCR in peripheral blood mononuclear cells (PBMC) from 61 MS patients, 9 R92Q carriers and 52 non-carriers (CT and CC genotypes for SNP rs4149584, respectively). Molecular dynamic studies revealed that the R92Q mutation increased the contact area between receptor and TNF (1070 and 1388Å2 for native and mutated receptor) and decreased the distance between them (28.7 to 27.9Å), while Van der Waals and electrostatic interaction energies were increased. In PBMC from MS patients carrying the R92Q mutation, CASP3 mRNA expression levels were significantly increased compared to non-carriers, whereas a trend was observed for TRAF2. These data suggest that the R92Q mutation gives rise to a stronger interaction between the receptor and its ligand, which results in the potentiation of TNF-mediated pathways. Although further studies are needed, these functional changes may be related with the modulation in disease course reported in MS patients carrying the R92Q mutation.
[Display omitted]
•Models of TNF receptor 1, native and with the R92Q mutation, were constructed.•TNF-R1 models bound or not to TNF were submitted to molecular dynamics.•The R92Q mutation increased the interaction energy between receptor and TNF.•CASP3 mRNA expression increased in MS patients carrying the R92Q mutation. |
---|---|
AbstractList | Abstract The tumor necrosis factor receptor superfamily, member 1A ( TNFRSF1A ) gene encodes the TNF-R1, one of the main TNF receptors that mediates its inflammatory actions. In a recent study, serum levels of the soluble TNF-R1 and mRNA levels of the full-length receptor were found to be significantly increased in multiple sclerosis (MS) patients carrying the R92Q mutation. Interestingly, R92Q-mutated patients were younger at disease onset and progressed slower as compared to non-carriers. Building on these previous findings, here we aimed to investigate by means of both in silico and in vitro approaches the mechanisms relating the R92Q substitution with functional changes of the receptor and their potential effects modulating MS disease course. Models of the extracellular domains of the human TNF-R1 and human TNF-R1 carrying the R92Q mutation, alone or bound to TNF, were constructed and submitted to molecular dynamics. TRAF2 and CASP3 mRNA expression levels were determined by real-time PCR in peripheral blood mononuclear cells (PBMC) from 61 MS patients, 9 R92Q carriers and 52 non-carriers (CT and CC genotypes for SNP rs4149584, respectively). Molecular dynamic studies revealed that the R92Q mutation increased the contact area between receptor and TNF (1070 and 1388 Å2 for native and mutated receptor) and decreased the distance between them (28.7 to 27.9 Å), while Van der Waals and electrostatic interaction energies were increased. In PBMC from MS patients carrying the R92Q mutation, CASP3 mRNA expression levels were significantly increased compared to non-carriers, whereas a trend was observed for TRAF2 . These data suggest that the R92Q mutation gives rise to a stronger interaction between the receptor and its ligand, which results in the potentiation of TNF-mediated pathways. Although further studies are needed, these functional changes may be related with the modulation in disease course reported in MS patients carrying the R92Q mutation. The tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) gene encodes the TNF-R1, one of the main TNF receptors that mediates its inflammatory actions. In a recent study, serum levels of the soluble TNF-R1 and mRNA levels of the full-length receptor were found to be significantly increased in multiple sclerosis (MS) patients carrying the R92Q mutation. Interestingly, R92Q-mutated patients were younger at disease onset and progressed slower as compared to non-carriers. Building on these previous findings, here we aimed to investigate by means of both in silico and in vitro approaches the mechanisms relating the R92Q substitution with functional changes of the receptor and their potential effects modulating MS disease course. Models of the extracellular domains of the human TNF-R1 and human TNF-R1 carrying the R92Q mutation, alone or bound to TNF, were constructed and submitted to molecular dynamics. TRAF2 and CASP3 mRNA expression levels were determined by real-time PCR in peripheral blood mononuclear cells (PBMC) from 61 MS patients, 9 R92Q carriers and 52 non-carriers (CT and CC genotypes for SNP rs4149584, respectively). Molecular dynamic studies revealed that the R92Q mutation increased the contact area between receptor and TNF (1070 and 1388Å2 for native and mutated receptor) and decreased the distance between them (28.7 to 27.9Å), while Van der Waals and electrostatic interaction energies were increased. In PBMC from MS patients carrying the R92Q mutation, CASP3 mRNA expression levels were significantly increased compared to non-carriers, whereas a trend was observed for TRAF2. These data suggest that the R92Q mutation gives rise to a stronger interaction between the receptor and its ligand, which results in the potentiation of TNF-mediated pathways. Although further studies are needed, these functional changes may be related with the modulation in disease course reported in MS patients carrying the R92Q mutation. [Display omitted] •Models of TNF receptor 1, native and with the R92Q mutation, were constructed.•TNF-R1 models bound or not to TNF were submitted to molecular dynamics.•The R92Q mutation increased the interaction energy between receptor and TNF.•CASP3 mRNA expression increased in MS patients carrying the R92Q mutation. The tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) gene encodes the TNF-R1, one of the main TNF receptors that mediates its inflammatory actions. In a recent study, serum levels of the soluble TNF-R1 and mRNA levels of the full-length receptor were found to be significantly increased in multiple sclerosis (MS) patients carrying the R92Q mutation. Interestingly, R92Q-mutated patients were younger at disease onset and progressed slower as compared to non-carriers. Building on these previous findings, here we aimed to investigate by means of both in silico and in vitro approaches the mechanisms relating the R92Q substitution with functional changes of the receptor and their potential effects modulating MS disease course. Models of the extracellular domains of the human TNF-R1 and human TNF-R1 carrying the R92Q mutation, alone or bound to TNF, were constructed and submitted to molecular dynamics. TRAF2 and CASP3 mRNA expression levels were determined by real-time PCR in peripheral blood mononuclear cells (PBMC) from 61 MS patients, 9 R92Q carriers and 52 non-carriers (CT and CC genotypes for SNP rs4149584, respectively). Molecular dynamic studies revealed that the R92Q mutation increased the contact area between receptor and TNF (1070 and 1388Å(2) for native and mutated receptor) and decreased the distance between them (28.7 to 27.9Å), while Van der Waals and electrostatic interaction energies were increased. In PBMC from MS patients carrying the R92Q mutation, CASP3 mRNA expression levels were significantly increased compared to non-carriers, whereas a trend was observed for TRAF2. These data suggest that the R92Q mutation gives rise to a stronger interaction between the receptor and its ligand, which results in the potentiation of TNF-mediated pathways. Although further studies are needed, these functional changes may be related with the modulation in disease course reported in MS patients carrying the R92Q mutation. The tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) gene encodes the TNF-R1, one of the main TNF receptors that mediates its inflammatory actions. In a recent study, serum levels of the soluble TNF-R1 and mRNA levels of the full-length receptor were found to be significantly increased in multiple sclerosis (MS) patients carrying the R92Q mutation. Interestingly, R92Q-mutated patients were younger at disease onset and progressed slower as compared to non-carriers. Building on these previous findings, here we aimed to investigate by means of both in silico and in vitro approaches the mechanisms relating the R92Q substitution with functional changes of the receptor and their potential effects modulating MS disease course. Models of the extracellular domains of the human TNF-R1 and human TNF-R1 carrying the R92Q mutation, alone or bound to TNF, were constructed and submitted to molecular dynamics. TRAF2 and CASP3 mRNA expression levels were determined by real-time PCR in peripheral blood mononuclear cells (PBMC) from 61 MS patients, 9 R92Q carriers and 52 non-carriers (CT and CC genotypes for SNP rs4149584, respectively). Molecular dynamic studies revealed that the R92Q mutation increased the contact area between receptor and TNF (1070 and 1388Aa2 for native and mutated receptor) and decreased the distance between them (28.7 to 27.9Aa), while Van der Waals and electrostatic interaction energies were increased. In PBMC from MS patients carrying the R92Q mutation, CASP3 mRNA expression levels were significantly increased compared to non-carriers, whereas a trend was observed for TRAF2. These data suggest that the R92Q mutation gives rise to a stronger interaction between the receptor and its ligand, which results in the potentiation of TNF-mediated pathways. Although further studies are needed, these functional changes may be related with the modulation in disease course reported in MS patients carrying the R92Q mutation. |
Author | Montalban, Xavier Malhotra, Sunny Comabella, Manuel Agulló, Luis Fissolo, Nicolás |
Author_xml | – sequence: 1 givenname: Luis surname: Agulló fullname: Agulló, Luis organization: Computational Biochemistry and Biophysics Laboratory (CBBL), U_Science Tech (UST), Universitat de Vic — Universitat Central de Catalunya (UVic-UCC), 08500 Vic, Barcelona, Spain – sequence: 2 givenname: Sunny surname: Malhotra fullname: Malhotra, Sunny organization: Servei de Neurologia–Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain – sequence: 3 givenname: Nicolás surname: Fissolo fullname: Fissolo, Nicolás organization: Servei de Neurologia–Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain – sequence: 4 givenname: Xavier surname: Montalban fullname: Montalban, Xavier organization: Servei de Neurologia–Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain – sequence: 5 givenname: Manuel surname: Comabella fullname: Comabella, Manuel organization: Servei de Neurologia–Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26616867$$D View this record in MEDLINE/PubMed |
BookMark | eNqNUk1v1DAUtFAR3Rb-QpUjlyz-SPwhIQSqKCAVEG05W17nuXVI7GInoP33ON3upQfak-XnmfF7M-8IHYQYAKETgtcEE_6mX_cB5hT9uKaYtKW4xpg9QysiBa1lQ8kBWhVgW7eCykN0lHOPC5A16gU6pJwTLrlYocuvcQA7DyZV3TaY0dtcmdBVPkzJWBiGu6fsr4MZfLiuoqumG6iuvp3VF6T666ebu_uFoj-qcZ7M5GN4iZ47M2R4dX8eo59nH69OP9fn3z99Of1wXtuWkKkW3Ckujdo4Q5zjirKNIpQSYQ1pGGWUtrJRrgNFjTGiU0yAlMw6Do43ZZRj9Hqne5vi7xnypEefl55NgDhnTYRsKcNYiidAmWwkEUQW6Mk9dN6M0Onb5EeTtnrvWQG83QFsijkncNr63eDFMj9ogvUSke71PiK9RLTUS0SFzh_Q9z88Sny_I0Lx9I-HpLP1ECx0PoGddBf94xLvHkjYkqq3ZvgFW8h9nFPJudihM9VYXy4LtOxPMRvjRon_Czylg3-jw9e1 |
CitedBy_id | crossref_primary_10_1111_iji_12388 crossref_primary_10_1002_minf_201800011 crossref_primary_10_1134_S1819712423020150 crossref_primary_10_1016_j_nrl_2022_07_001 crossref_primary_10_1177_1759720X211037178 crossref_primary_10_1177_2058738418787990 crossref_primary_10_1111_jgs_15268 crossref_primary_10_1016_j_nrleng_2022_07_002 crossref_primary_10_31857_S1027813323020152 crossref_primary_10_3389_fimmu_2017_00299 |
Cites_doi | 10.1097/00005792-200209000-00002 10.1016/0263-7855(96)00018-5 10.1006/meth.2001.1262 10.1016/S0021-9258(18)71533-0 10.1016/S0968-0004(97)01164-X 10.1016/j.jneuroim.2011.03.004 10.1021/ct100578z 10.1002/jcc.20289 10.1006/jmbi.1993.1626 10.1002/art.10429 10.1212/01.wnl.0000436612.66328.8a 10.1073/pnas.0504921102 10.1021/bi3006626 10.1016/j.jmb.2004.04.058 10.1074/jbc.M110.208215 10.1212/WNL.0b013e318294b2d6 10.1093/nar/gki398 10.1016/0092-8674(93)90132-A 10.1002/art.21964 10.1084/jem.20040435 10.1016/S1043-4666(03)00117-0 10.1086/321976 10.1038/ng.401 |
ContentType | Journal Article |
Copyright | 2015 Elsevier B.V. Elsevier B.V. Copyright © 2015 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2015 Elsevier B.V. – notice: Elsevier B.V. – notice: Copyright © 2015 Elsevier B.V. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7T5 7TK 8FD FR3 H94 P64 RC3 |
DOI | 10.1016/j.jneuroim.2015.10.003 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Immunology Abstracts Neurosciences Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts Genetics Abstracts |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Genetics Abstracts Technology Research Database AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts |
DatabaseTitleList | MEDLINE MEDLINE - Academic Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1872-8421 |
EndPage | 20 |
ExternalDocumentID | 26616867 10_1016_j_jneuroim_2015_10_003 S0165572815300497 1_s2_0_S0165572815300497 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 4.4 457 4CK 4G. 5GY 5VS 7-5 71M 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABMZM ABTEW ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACVFH ADBBV ADCNI ADEZE AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AFPUW AFRHN AFTJW AFXIZ AGCQF AGEKW AGHFR AGUBO AGWIK AGYEJ AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AXJTR BKOJK BLXMC BNPGV CJTIS CNWQP CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA HMO HMQ IHE J1W KOM L7B LUGTX LX8 M29 M2V M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSI SSN SSZ T5K UNMZH Z5R ~G- .GJ 29L 53G AACTN AAQXK ABWVN ABXDB ACRPL ADMUD ADNMO AFCTW AFJKZ AFKWA AHHHB AJOXV AKRLJ AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HDW HMG HMK HVGLF HZ~ R2- RIG SAE SEW SIN SNS WUQ XJT ZGI EFLBG ~HD AAYXX AGQPQ AGRNS AIGII APXCP CITATION CGR CUY CVF ECM EIF NPM 7X8 ACLOT 7T5 7TK 8FD FR3 H94 P64 RC3 |
ID | FETCH-LOGICAL-c511t-76f968a9bfa1ff6923b912217ca14323225849fde92aaa7d937e883cf6ef64153 |
IEDL.DBID | AIKHN |
ISSN | 0165-5728 |
IngestDate | Sun Sep 28 07:11:17 EDT 2025 Sun Sep 28 06:00:19 EDT 2025 Thu Apr 03 06:59:14 EDT 2025 Tue Jul 01 01:53:29 EDT 2025 Thu Apr 24 22:53:07 EDT 2025 Thu Sep 18 02:46:31 EDT 2025 Sun Feb 23 10:19:12 EST 2025 Tue Aug 26 17:33:13 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Multiple sclerosis Tumor necrosis factor CASP3 R92Q mutation Molecular dynamics TNF receptor-associated periodic syndrome TRAF2 TNF receptor 1 mRNA expression |
Language | English |
License | Copyright © 2015 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c511t-76f968a9bfa1ff6923b912217ca14323225849fde92aaa7d937e883cf6ef64153 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 26616867 |
PQID | 1738481718 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_1785230087 proquest_miscellaneous_1738481718 pubmed_primary_26616867 crossref_citationtrail_10_1016_j_jneuroim_2015_10_003 crossref_primary_10_1016_j_jneuroim_2015_10_003 elsevier_sciencedirect_doi_10_1016_j_jneuroim_2015_10_003 elsevier_clinicalkeyesjournals_1_s2_0_S0165572815300497 elsevier_clinicalkey_doi_10_1016_j_jneuroim_2015_10_003 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-12-15 |
PublicationDateYYYYMMDD | 2015-12-15 |
PublicationDate_xml | – month: 12 year: 2015 text: 2015-12-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Journal of neuroimmunology |
PublicationTitleAlternate | J Neuroimmunol |
PublicationYear | 2015 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Caminero, Comabella, Montalban (bb0025) 2011; 234 Aksentijevich, Galon, Soares, Mansfield, Hull (bb0005) 2001; 69 Sobolev, Eyal, Gerzon, Potapov, Babor (bb0115) 2005; 33 Comabella, Caminero, Malhotra, Agulló, Fernández (bb0030) 2013; 80 Phillips, Braun, Wang, Gumbart, Tajkhorshid (bb0100) 2005; 26 Lewis, Valley, Sachs (bb0070) 2012; 51 Naismith, Sprang (bb0080) 1998; 23 Olsson, Søndergard, Rostkowski, Jensen (bb0085) 2011; 7 Rebelo, Bainbridge, Amel-Kashipaz, Radford, Powell (bb0105) 2006; 54 Borovecki, Lovrecic, Zhou, Jeong, Then (bb0020) 2005; 102 Hull, Drewe, Aksentijevich, Singh, Wong (bb0055) 2002; 81 Banner, D'Arcy, Janes, Gentz, Schoenfeld (bb0015) 1993; 73 Humphrey, Dalke, Schulten (bb0060) 1996; 14 Ottoboni, Frohlich, Lee, Healy, Keenan (bb0095) 2013; 81 An, Kim, Song, Park, Kim (bb0010) 2011; 286 Xanthoulea, Pasparakis, Kousteni, Brakebusch, Wallach (bb0120) 2004; 200 Ihnatko, Kubes (bb0065) 2007; 26 O'Sullivan, Suhre, Abergel, Higgins, Notredame (bb0090) 2004; 340 Dodé, André, Bienvenu, Hausfater, Pêcheux (bb0040) 2002; 46 De Jager, Jia, Wang, de Bakker, Ottoboni (bb0035) 2009; 4 Eck, Sprang (bb0045) 1989; 264 Ermert, Pantazis, Duncker, Grimminger, Seeger (bb0050) 2003; 22 Livak, Schmittgen (bb0075) 2001; 25 Sali, Blundell (bb0110) 1993; 234 Comabella (10.1016/j.jneuroim.2015.10.003_bb0030) 2013; 80 Sobolev (10.1016/j.jneuroim.2015.10.003_bb0115) 2005; 33 Humphrey (10.1016/j.jneuroim.2015.10.003_bb0060) 1996; 14 Xanthoulea (10.1016/j.jneuroim.2015.10.003_bb0120) 2004; 200 Caminero (10.1016/j.jneuroim.2015.10.003_bb0025) 2011; 234 Dodé (10.1016/j.jneuroim.2015.10.003_bb0040) 2002; 46 Borovecki (10.1016/j.jneuroim.2015.10.003_bb0020) 2005; 102 De Jager (10.1016/j.jneuroim.2015.10.003_bb0035) 2009; 4 Livak (10.1016/j.jneuroim.2015.10.003_bb0075) 2001; 25 Ottoboni (10.1016/j.jneuroim.2015.10.003_bb0095) 2013; 81 Sali (10.1016/j.jneuroim.2015.10.003_bb0110) 1993; 234 Aksentijevich (10.1016/j.jneuroim.2015.10.003_bb0005) 2001; 69 Ihnatko (10.1016/j.jneuroim.2015.10.003_bb0065) 2007; 26 Naismith (10.1016/j.jneuroim.2015.10.003_bb0080) 1998; 23 Ermert (10.1016/j.jneuroim.2015.10.003_bb0050) 2003; 22 O'Sullivan (10.1016/j.jneuroim.2015.10.003_bb0090) 2004; 340 Rebelo (10.1016/j.jneuroim.2015.10.003_bb0105) 2006; 54 Phillips (10.1016/j.jneuroim.2015.10.003_bb0100) 2005; 26 Banner (10.1016/j.jneuroim.2015.10.003_bb0015) 1993; 73 Hull (10.1016/j.jneuroim.2015.10.003_bb0055) 2002; 81 An (10.1016/j.jneuroim.2015.10.003_bb0010) 2011; 286 Eck (10.1016/j.jneuroim.2015.10.003_bb0045) 1989; 264 Lewis (10.1016/j.jneuroim.2015.10.003_bb0070) 2012; 51 Olsson (10.1016/j.jneuroim.2015.10.003_bb0085) 2011; 7 |
References_xml | – volume: 200 start-page: 367 year: 2004 end-page: 376 ident: bb0120 article-title: Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases publication-title: J. Exp. Med. – volume: 23 start-page: 74 year: 1998 end-page: 79 ident: bb0080 article-title: Modularity in the TNF-receptor family publication-title: Trends Biochem. Sci. – volume: 14 start-page: 33 year: 1996 end-page: 38 ident: bb0060 article-title: VMD: visual molecular dynamics publication-title: J. Mol. Graph. – volume: 7 start-page: 525 year: 2011 end-page: 537 ident: bb0085 article-title: PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions publication-title: J. Chem. Theory Comput. – volume: 264 start-page: 17595 year: 1989 end-page: 17605 ident: bb0045 article-title: The structure of tumor necrosis factor-alpha at 2.6 publication-title: J. Biol. Chem. – volume: 102 start-page: 11023 year: 2005 end-page: 11028 ident: bb0020 article-title: Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease publication-title: Proc. Natl. Acad. Sci. U. S. A. – volume: 234 start-page: 779 year: 1993 end-page: 815 ident: bb0110 article-title: Comparative protein modelling by satisfaction of spatial restraints publication-title: J. Mol. Biol. – volume: 46 start-page: 2181 year: 2002 end-page: 2188 ident: bb0040 article-title: The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome publication-title: Arthritis Rheum. – volume: 234 start-page: 1 year: 2011 end-page: 6 ident: bb0025 article-title: Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story publication-title: J. Neuroimmunol. – volume: 22 start-page: 89 year: 2003 end-page: 100 ident: bb0050 article-title: In situ localization of TNFalpha/beta, TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue publication-title: Cytokine – volume: 80 start-page: 2010 year: 2013 end-page: 2016 ident: bb0030 article-title: TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis publication-title: Neurology – volume: 340 start-page: 385 year: 2004 end-page: 395 ident: bb0090 article-title: 3DCoffee: combining protein sequences and structures within multiple sequence alignments publication-title: J. Mol. Biol. – volume: 73 start-page: 431 year: 1993 end-page: 445 ident: bb0015 article-title: Crystal structure of the soluble human 55 publication-title: Cell – volume: 286 start-page: 11226 year: 2011 end-page: 11235 ident: bb0010 article-title: Crystallographic and mutational analysis of the CD40–CD154 complex and its implications for receptor activation publication-title: J. Biol. Chem. – volume: 81 start-page: 349 year: 2002 end-page: 368 ident: bb0055 article-title: The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder publication-title: Medicine (Baltimore) – volume: 26 start-page: 1781 year: 2005 end-page: 1802 ident: bb0100 article-title: Scalable molecular dynamics with NAMD publication-title: J. Comput. Chem. – volume: 26 start-page: 159 year: 2007 end-page: 167 ident: bb0065 article-title: TNF signaling: early events and phosphorylation publication-title: Gen. Physiol. Biophys. – volume: 51 start-page: 6545 year: 2012 end-page: 6555 ident: bb0070 article-title: TNFR1 signaling is associated with backbone conformational changes of receptor dimers consistent with overactivation in the R92Q TRAPS mutant publication-title: Biochemistry – volume: 81 start-page: 1891 year: 2013 end-page: 1899 ident: bb0095 article-title: Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus publication-title: Neurology – volume: 4 start-page: 776 year: 2009 end-page: 782 ident: bb0035 article-title: Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci publication-title: Nat. Genet. – volume: 69 start-page: 301 year: 2001 end-page: 314 ident: bb0005 article-title: The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers publication-title: Am. J. Hum. Genet. – volume: 54 start-page: 2674 year: 2006 end-page: 2687 ident: bb0105 article-title: Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function publication-title: Arthritis Rheum. – volume: 25 start-page: 402 year: 2001 end-page: 408 ident: bb0075 article-title: Analysis of relative gene expression data using real-time quantitative PCR and the 2(− publication-title: Methods – volume: 33 start-page: W39 year: 2005 end-page: W43 ident: bb0115 article-title: SPACE: a suite of tools for protein structure prediction and analysis based on complementarity and environment publication-title: Nucleic Acids Res. – volume: 81 start-page: 349 year: 2002 ident: 10.1016/j.jneuroim.2015.10.003_bb0055 article-title: The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder publication-title: Medicine (Baltimore) doi: 10.1097/00005792-200209000-00002 – volume: 14 start-page: 33 year: 1996 ident: 10.1016/j.jneuroim.2015.10.003_bb0060 article-title: VMD: visual molecular dynamics publication-title: J. Mol. Graph. doi: 10.1016/0263-7855(96)00018-5 – volume: 25 start-page: 402 year: 2001 ident: 10.1016/j.jneuroim.2015.10.003_bb0075 article-title: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method publication-title: Methods doi: 10.1006/meth.2001.1262 – volume: 264 start-page: 17595 year: 1989 ident: 10.1016/j.jneuroim.2015.10.003_bb0045 article-title: The structure of tumor necrosis factor-alpha at 2.6Å resolution. Implications for receptor binding publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(18)71533-0 – volume: 23 start-page: 74 year: 1998 ident: 10.1016/j.jneuroim.2015.10.003_bb0080 article-title: Modularity in the TNF-receptor family publication-title: Trends Biochem. Sci. doi: 10.1016/S0968-0004(97)01164-X – volume: 234 start-page: 1 year: 2011 ident: 10.1016/j.jneuroim.2015.10.003_bb0025 article-title: Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story publication-title: J. Neuroimmunol. doi: 10.1016/j.jneuroim.2011.03.004 – volume: 7 start-page: 525 year: 2011 ident: 10.1016/j.jneuroim.2015.10.003_bb0085 article-title: PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions publication-title: J. Chem. Theory Comput. doi: 10.1021/ct100578z – volume: 26 start-page: 1781 year: 2005 ident: 10.1016/j.jneuroim.2015.10.003_bb0100 article-title: Scalable molecular dynamics with NAMD publication-title: J. Comput. Chem. doi: 10.1002/jcc.20289 – volume: 234 start-page: 779 year: 1993 ident: 10.1016/j.jneuroim.2015.10.003_bb0110 article-title: Comparative protein modelling by satisfaction of spatial restraints publication-title: J. Mol. Biol. doi: 10.1006/jmbi.1993.1626 – volume: 46 start-page: 2181 year: 2002 ident: 10.1016/j.jneuroim.2015.10.003_bb0040 article-title: The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome publication-title: Arthritis Rheum. doi: 10.1002/art.10429 – volume: 81 start-page: 1891 year: 2013 ident: 10.1016/j.jneuroim.2015.10.003_bb0095 article-title: Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus publication-title: Neurology doi: 10.1212/01.wnl.0000436612.66328.8a – volume: 102 start-page: 11023 year: 2005 ident: 10.1016/j.jneuroim.2015.10.003_bb0020 article-title: Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease publication-title: Proc. Natl. Acad. Sci. U. S. A. doi: 10.1073/pnas.0504921102 – volume: 51 start-page: 6545 year: 2012 ident: 10.1016/j.jneuroim.2015.10.003_bb0070 article-title: TNFR1 signaling is associated with backbone conformational changes of receptor dimers consistent with overactivation in the R92Q TRAPS mutant publication-title: Biochemistry doi: 10.1021/bi3006626 – volume: 340 start-page: 385 year: 2004 ident: 10.1016/j.jneuroim.2015.10.003_bb0090 article-title: 3DCoffee: combining protein sequences and structures within multiple sequence alignments publication-title: J. Mol. Biol. doi: 10.1016/j.jmb.2004.04.058 – volume: 286 start-page: 11226 year: 2011 ident: 10.1016/j.jneuroim.2015.10.003_bb0010 article-title: Crystallographic and mutational analysis of the CD40–CD154 complex and its implications for receptor activation publication-title: J. Biol. Chem. doi: 10.1074/jbc.M110.208215 – volume: 80 start-page: 2010 year: 2013 ident: 10.1016/j.jneuroim.2015.10.003_bb0030 article-title: TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0b013e318294b2d6 – volume: 26 start-page: 159 year: 2007 ident: 10.1016/j.jneuroim.2015.10.003_bb0065 article-title: TNF signaling: early events and phosphorylation publication-title: Gen. Physiol. Biophys. – volume: 33 start-page: W39 year: 2005 ident: 10.1016/j.jneuroim.2015.10.003_bb0115 article-title: SPACE: a suite of tools for protein structure prediction and analysis based on complementarity and environment publication-title: Nucleic Acids Res. doi: 10.1093/nar/gki398 – volume: 73 start-page: 431 year: 1993 ident: 10.1016/j.jneuroim.2015.10.003_bb0015 article-title: Crystal structure of the soluble human 55kd TNF receptor–human TNF beta complex: implications for TNF receptor activation publication-title: Cell doi: 10.1016/0092-8674(93)90132-A – volume: 54 start-page: 2674 year: 2006 ident: 10.1016/j.jneuroim.2015.10.003_bb0105 article-title: Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function publication-title: Arthritis Rheum. doi: 10.1002/art.21964 – volume: 200 start-page: 367 year: 2004 ident: 10.1016/j.jneuroim.2015.10.003_bb0120 article-title: Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases publication-title: J. Exp. Med. doi: 10.1084/jem.20040435 – volume: 22 start-page: 89 year: 2003 ident: 10.1016/j.jneuroim.2015.10.003_bb0050 article-title: In situ localization of TNFalpha/beta, TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue publication-title: Cytokine doi: 10.1016/S1043-4666(03)00117-0 – volume: 69 start-page: 301 year: 2001 ident: 10.1016/j.jneuroim.2015.10.003_bb0005 article-title: The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers publication-title: Am. J. Hum. Genet. doi: 10.1086/321976 – volume: 4 start-page: 776 year: 2009 ident: 10.1016/j.jneuroim.2015.10.003_bb0035 article-title: Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci publication-title: Nat. Genet. doi: 10.1038/ng.401 |
SSID | ssj0015349 |
Score | 2.2186394 |
Snippet | The tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A) gene encodes the TNF-R1, one of the main TNF receptors that mediates its inflammatory... Abstract The tumor necrosis factor receptor superfamily, member 1A ( TNFRSF1A ) gene encodes the TNF-R1, one of the main TNF receptors that mediates its... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 12 |
SubjectTerms | Allergy and Immunology Arginine - genetics Biological Evolution CASP3 Caspase 3 - genetics Caspase 3 - metabolism Glutamine - genetics Humans Models, Molecular Molecular dynamics mRNA expression Multiple sclerosis Mutation - genetics Neurology Nonlinear Dynamics R92Q mutation Receptors, Tumor Necrosis Factor, Type I - genetics RNA, Messenger - metabolism Signal Transduction - genetics TNF receptor 1 TNF Receptor-Associated Factor 2 - genetics TNF Receptor-Associated Factor 2 - metabolism TNF receptor-associated periodic syndrome TRAF2 Tumor necrosis factor |
Title | Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0165572815300497 https://www.clinicalkey.es/playcontent/1-s2.0-S0165572815300497 https://dx.doi.org/10.1016/j.jneuroim.2015.10.003 https://www.ncbi.nlm.nih.gov/pubmed/26616867 https://www.proquest.com/docview/1738481718 https://www.proquest.com/docview/1785230087 |
Volume | 289 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED9tnYR4QbDx0QGTkRBvaRMn_shjNVEVqlai28TeLOfDUiuWTrR92At_O3eOU4HQAMFLosQ5xTr7fD-f7wPgrZMVpVGrI2dtFmVVnEfaObxYSxFd3AqfXX82l5Or7OO1uD6A8y4Whtwqw9rfrul-tQ5vhoGbw9vlcnhBgThCcY0ySzhXHcIRR22ve3A0-jCdzPeHCSJtUTB-HxHBD4HCq8HK541cUlB6Igbe0Su9T0fdh0G9Lho_hkcBRLJR288ncFA3x3AyanADfXPH3jHv1unt5cfwYBZOz0_gYtbVwmVVW4h-w2xTsSUZeMmC75vIo8NSkDpbO4bwkF3Ox9EiYWSx9c-LnH9iN7v2DP8pXI3fX55PolBUISoRW20jJV0utc0LZxPnJOK7Ik84bkxKi9CJk3zrLHdVnXNrraoQvtRap6WTtZOo7dNn0GvWTf0CGDZWVpSlcggS6ETWlrFVseLC5WVRZH0QHRtNGTKOU-GLL6ZzLVuZjv2G2E_vkf19GO7pbtucG3-kUN0omS6iFNdAg2rh3yjrTRDljUnMhpvY_DLd-pDvKX-asX_11zfdVDIozjTCtqnXO_ybSqnAASKG332jyZYfa-zD83Ye7vlEeEtqqU7_o3cv4SE9kdNOIl5Bb_t1V79G6LUtzuBw8C05CwJG9-ni8_Q7dGIuVw |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxEB6VVAIuCFooAQpGQty22Zdfx6hqlNImEm0q9WZ5d20pEd1UJDnw75nx7kYgVFrBZaW1PbI19tifx_MA-ORFRWHUXOStzaO8inWkvMePteTRlVoeoutPpmJ8lX-55tc7cNz5wpBZZbv3N3t62K3bkkHLzcHtfD64JEccLlOFMks4Vz6C3ZySWvdgd3h6Np5uHxN41qBgbB8RwS-OwoujRYgbOSen9IQfBUOv7K4z6i4MGs6i0XN41oJINmzG-QJ2XL0H-8MaL9A3P9hnFsw6g758Dx5P2tfzfbicdLlwWdUkol8xW1dsTgpe0uCHKrLosOSkzpaeITxks-koukgYaWzD_4VOv7KbTfOG_xKuRiez43HUJlWISsRW60gKr4WyuvA28V4gvit0kuLFpLQInVKSb5VrXzmdWmtlhfDFKZWVXjgv8LTPXkGvXtbuNTCsrCwvS-kRJNCLrC1jK2OZcq_Losj7wDs2mrKNOE6JL76ZzrRsYTr2G2I_lSP7-zDY0t02MTfupZDdLJnOoxT3QIPHwr9RulUryiuTmFVqYvPHcuuD3lL-tmIf1OvHbikZFGeaYVu75QZ7kxklOEDE8Lc2inT5scIxHDTrcMsnwltCCfnmP0b3AZ6MZ5Nzc346PXsLT6mGDHgS_g566-8bd4gwbF28b8XsJxm2Lpo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+dynamics+and+intracellular+signaling+of+the+TNF-R1+with+the+R92Q+mutation&rft.jtitle=Journal+of+neuroimmunology&rft.au=Agull%C3%B3%2C+Luis&rft.au=Malhotra%2C+Sunny&rft.au=Fissolo%2C+Nicol%C3%A1s&rft.au=Montalban%2C+Xavier&rft.date=2015-12-15&rft.issn=0165-5728&rft.volume=289&rft.spage=12&rft.epage=20&rft_id=info:doi/10.1016%2Fj.jneuroim.2015.10.003&rft.externalDBID=ECK1-s2.0-S0165572815300497&rft.externalDocID=1_s2_0_S0165572815300497 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01655728%2FS0165572815X00117%2Fcov150h.gif |